S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
Log in
NASDAQ:SUPN

Supernus Pharmaceuticals Stock Forecast, Price & News

$21.76
+0.09 (+0.42 %)
(As of 12/3/2020 04:43 PM ET)
Add
Compare
Today's Range
$21.58
Now: $21.76
$22.28
50-Day Range
$17.70
MA: $20.94
$24.95
52-Week Range
$13.12
Now: $21.76
$25.82
Volume365,095 shs
Average Volume535,565 shs
Market Capitalization$1.15 billion
P/E Ratio9.85
Dividend YieldN/A
Beta1.39
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in the United States. The company offers Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and in children 6 to 17 years of age; and Trokendi XR, an extended release topiramate, which is used for the prophylaxis of migraine headache, as well as for the treatment of epilepsy. Its product candidates comprise SPN-812, a viloxazine hydrochloride, which has completed phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-809, a viloxazine hydrochloride, which is in phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine, which is in phase III clinical trial for the treatment of bipolar disorder; and SPN-817 that is in phase I clinical trial to treat severe pediatric epilepsy disorders. The company markets its products through pharmaceutical wholesalers and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a phase II clinical program for NV-5138 in treatment-resistant depression. Supernus Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Rockville, Maryland.
Supernus Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.62 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:SUPN
CUSIP86845910
Phone301-838-2500
Employees464

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$392.76 million
Cash Flow$2.71 per share
Book Value$11.35 per share

Profitability

Net Income$113.06 million

Miscellaneous

Market Cap$1.15 billion
Next Earnings Date2/23/2021 (Estimated)
OptionableOptionable
$21.76
+0.09 (+0.42 %)
(As of 12/3/2020 04:43 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

How has Supernus Pharmaceuticals' stock been impacted by Coronavirus?

Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SUPN shares have increased by 34.4% and is now trading at $21.71.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Supernus Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Supernus Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Supernus Pharmaceuticals?

Wall Street analysts have given Supernus Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Supernus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Supernus Pharmaceuticals' next earnings date?

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Supernus Pharmaceuticals
.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) announced its quarterly earnings data on Tuesday, November, 3rd. The specialty pharmaceutical company reported $0.74 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.27 by $0.47. The specialty pharmaceutical company earned $155.10 million during the quarter, compared to analysts' expectations of $130.76 million. Supernus Pharmaceuticals had a return on equity of 19.44% and a net margin of 27.85%. The business's revenue for the quarter was up 52.1% on a year-over-year basis. During the same quarter last year, the business posted $0.54 earnings per share.
View Supernus Pharmaceuticals' earnings history
.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Tuesday, November, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $500-525 million, compared to the consensus revenue estimate of $486.54 million.

What price target have analysts set for SUPN?

3 equities research analysts have issued twelve-month target prices for Supernus Pharmaceuticals' stock. Their forecasts range from $24.00 to $31.00. On average, they anticipate Supernus Pharmaceuticals' stock price to reach $26.33 in the next year. This suggests a possible upside of 21.3% from the stock's current price.
View analysts' price targets for Supernus Pharmaceuticals
.

Are investors shorting Supernus Pharmaceuticals?

Supernus Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 5,650,000 shares, an increase of 8.9% from the October 31st total of 5,190,000 shares. Based on an average trading volume of 490,200 shares, the short-interest ratio is presently 11.5 days. Currently, 11.2% of the company's stock are short sold.
View Supernus Pharmaceuticals' Short Interest
.

Who are some of Supernus Pharmaceuticals' key competitors?

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the following people:
  • Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 59, Pay $1.49M)
  • Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 63, Pay $537.2k)
  • Ms. Tami T. Martin, Sr. VP of Regulatory Affairs (Age 65, Pay $450.28k)
  • Mr. Gregory S. Patrick, Advisor (Age 69, Pay $555.57k)
  • Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 68, Pay $584.04k)
  • Mr. James Patrick Kelly, Exec. VP & CFO (Age 54)
  • Dr. Todd Horich M.B.A., Ph.D., VP of Marketing
  • Mr. Taylor Raiford, VP of Sales
  • Dr. Bryan A. Roecklein, VP of Corp. Devel.
  • Mr. Frank Mottola, Sr. VP of Quality, GMP Operations & Information Technology (Age 48)

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include GW&K Investment Management LLC (1.99%), Fuller & Thaler Asset Management Inc. (1.87%), Ashford Capital Management Inc. (1.55%), LSV Asset Management (1.54%), Victory Capital Management Inc. (0.92%) and Charles Schwab Investment Management Inc. (0.85%). Company insiders that own Supernus Pharmaceuticals stock include Frederick M Hudson, Gregory S Patrick and Jack A Khattar.
View institutional ownership trends for Supernus Pharmaceuticals
.

Which institutional investors are selling Supernus Pharmaceuticals stock?

SUPN stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Sofinnova Investments Inc., WINTON GROUP Ltd, Great West Life Assurance Co. Can, Squarepoint Ops LLC, Nisa Investment Advisors LLC, AQR Capital Management LLC, and Principal Financial Group Inc.. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Frederick M Hudson, and Gregory S Patrick.
View insider buying and selling activity for Supernus Pharmaceuticals
.

Which institutional investors are buying Supernus Pharmaceuticals stock?

SUPN stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., GW&K Investment Management LLC, Federated Hermes Inc., Ashford Capital Management Inc., LSV Asset Management, Charles Schwab Investment Management Inc., Royce & Associates LP, and Scout Investments Inc..
View insider buying and selling activity for Supernus Pharmaceuticals
.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $21.71.

How big of a company is Supernus Pharmaceuticals?

Supernus Pharmaceuticals has a market capitalization of $1.14 billion and generates $392.76 million in revenue each year. The specialty pharmaceutical company earns $113.06 million in net income (profit) each year or $2.10 on an earnings per share basis. Supernus Pharmaceuticals employs 464 workers across the globe.

What is Supernus Pharmaceuticals' official website?

The official website for Supernus Pharmaceuticals is www.supernus.com.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.